Rexahn Pharmaceuticals, Inc. Secures Approval in Europe to Conduct a First-in-Human Trial of RX-3117 in Solid Tumors

Published: Jan 18, 2012

ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing oncology and CNS therapeutics, today announced that it has secured Hungarian Regulatory Authority and Ethics Committee approval for Rexahn’s initial Clinical Trial Application (CTA). This allows Rexahn to initiate an exploratory first-in-human Phase I clinical trial of RX-3117.

Back to news